SEARCH

SEARCH BY CITATION

References

  • 1
    Petras R. Non-neoplastic intestinal diseases. In: MillsSE ed. Sternberg’s Diagnostic Surgical Pathology, 4th edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2004; 14751541.
  • 2
    Castro-Fernández M, Sánchez-Muñoz D, Ruíz-Granados E, Merchante N, Corzo J. Coexistence of pyoderma gangrenosum and Sweet’s syndrome in a patient with ulcerative colitis. Am J Gastroenterol 2007; 102: 28652866.
    Direct Link:
  • 3
    Crispino P, Pica R, Angelucci E et al. Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature. Int J Colorectal Dis 2007; 22: 553558.
  • 4
    Bourikas LA, Tzardi M, Hatzidakis A, Koutroubakis IE. Small bowel perforation due to non-Hodgkin-lymphoma in a patient with ulcerative colitis and systemic lupus erythematosus. Dig Liver Dis 2008; 40: 144.
  • 5
    Asada Y, Isomoto H, Shikuwa S et al. Development of ulcerative colitis during the course of rheumatoid arthritis: association with selective IgA deficiency. World J Gastroenterol 2006; 12: 52405243.
  • 6
    Molta CT, Khan MA, Aponte CJ, Reynolds TL, Macintyre SS. Familial occurrence of systemic sclerosis, rheumatoid arthritis and other immunological disorders: report of two kindreds with study of HLA antigens and review of the literature. Clin Exp Rheumatol 1989; 7: 229326.
  • 7
    Turhal N, DeLuca VA Jr. Ulcerative colitis and scleroderma. A coincidental relationship? J Clin Gastroenterol 1994; 18: 218219.
  • 8
    DeLuca VA Jr, Spiro HM, Thayer WR. Ulcerative colitis and scleroderma. Gastroenterology 1965; 49: 433438.
  • 9
    Freeman HJ. Colorectal cancer risk in Crohn’s disease. World J Gastroenterol 2008; 14: 18101811.
  • 10
    Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D. Cancer in patients with ulcerative colitis, Crohn’s disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol 2008; 20: 297304.
  • 11
    Zeidan A, Sham R, Shapiro J, Baratta A, Kouides P. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease who received infliximab therapy. Leuk Lymphoma 2007; 48: 14101413.
  • 12
    Wick JY, Zanni GR. Rheumatoid arthritis – Crohn’s disease connection. Consult Pharm 2005; 20: 110111. 115–122.
  • 13
    Szollosi Z, Tarr T, Kiss E. Crohn disease versus systemic lupus erythematosus: an autopsy diagnosis of predominantly extraintestinal Crohn disease. Inflamm Bowel Dis 2004; 10: 702703.
  • 14
    Marks DJ, Segal AW. Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol 2008; 214: 260266.
  • 15
    Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F. Innate and adaptive immune responses related to IBD pathogenesis. Curr Gastroenterol Rep 2007; 9: 508512.
  • 16
    Takehara K. Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 2004; 22: S87S89.
  • 17
    Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr Int 2002; 44: 196198.
  • 18
    Kaneko K, Nagaoka R, Ohtomo Y, Shimizu T, Yamashiro Y. Effect of mizoribine on IL-6 release by peripheral blood mononuclear cells. Nephron 2002; 91: 506508.
  • 19
    Tanaka E, Inoue E, Kawaguchi Y et al. Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol 2006; 16: 214219.
  • 20
    Nozu K, Iijima K, Kamioka I et al. High-dose mizoribine treatment for adolescents with systemic lupus erythematosus. Pediatr Int 2006; 48: 152157.
  • 21
    Tanaka H, Tsugawa K, Tsuruga K et al. Mizoribine for the treatment of lupus nephritis in children and adolescents. Clin Nephrol 2004; 62: 412417.
  • 22
    Yumura W, Suganuma S, Uchida K et al. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol 2005; 64: 2834.
  • 23
    Tanaka H, Tsugawa K, Nakahata T, Kudo M, Suzuki K, Ito E. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis. Clin Nephrol 2005; 63: 417422.
  • 24
    Kuroda T, Hirose S, Tanabe N et al. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy. Mod Rheumatol 2007; 17: 206212.
  • 25
    Tsubouchi Y, Fukuda W, Kawahito Y et al. A case of lupus nephritis improved after appropriately adjusting the dosage of mizoribine. Mod Rheumatol 2008; 18: 9195.
  • 26
    Fujieda M, Ishihara M, Morita T et al. Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 2008; 69: 179184.
  • 27
    Doi T, Masaki T, Shiraki N, Kawai T, Yorioka N. Oral mizoribine pulse therapy for steroid-dependent focal segmental glomerulosclerosis. Clin Nephrol 2008; 69: 433435.